Chengdu, China

Pengyi Luo

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2021-2023

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Pengyi Luo: Innovator in Recombinant Fusion Proteins

Introduction

Pengyi Luo is a notable inventor based in Chengdu, China. He has made significant contributions to the field of biotechnology, particularly in the development of recombinant fusion proteins. With a total of 2 patents, his work focuses on innovative therapeutic solutions.

Latest Patents

Luo's latest patents include a groundbreaking invention related to human neuregulin-1 (NRG-1) recombinant fusion protein compositions. This invention involves a recombinant fusion protein that comprises a fragment of the cardioprotective protein neuregulin-1 (NRG-1) fused to a monoclonal antibody (mAb) backbone. The method outlined in this patent aims to treat diseases or conditions in subjects by administering a therapeutically effective amount of the recombinant fusion protein or a pharmaceutical composition containing it.

Career Highlights

Throughout his career, Pengyi Luo has worked with prominent companies in the biotechnology sector. Notably, he has been associated with Salubris Biotherapeutics, Inc. and Salubris (Chengdu) Biotech Co., Ltd. His experience in these organizations has contributed to his expertise in developing innovative therapeutic solutions.

Collaborations

Luo has collaborated with esteemed colleagues, including John H Li and Shengwei Li. These partnerships have further enhanced his research and development efforts in the field of biotechnology.

Conclusion

Pengyi Luo's contributions to the field of recombinant fusion proteins demonstrate his commitment to advancing medical science. His innovative patents and collaborations highlight his role as a key figure in biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…